Due to the diverse nature of its target, pain treatment warrants a wide range of options. The multitude of analgesics available today and the several
delivery methods devised for the best patient care signify the growth and importance of the pain treatment market.
Pain management and treatment deals with different levels of pain and over the years, options such as pharmacotherapy, radiation, or physical therapy, or
surgery have been used to treat pain. Innovation is the key to the pain treatment market and
companies have been consistently developing new and effective drugs to treat mild to severe pain.
The active pipeline of pain treatment and management presently holds more than 790 products at different stages of development. Competition in the market
is tough and even with the fact that the pain treatment market is considerably mature, the truth is that science and medicine can never give up on
innovation. Developing new therapies that are less toxic, less addictive, and more efficacious than existing medications is the challenge that players in
this market have to focus on to stay strong in the competition.
The significance of first-in-class drugs for pain treatment is vital and presents increasing investment opportunities for drug manufacturing companies. The
pain treatment market, in general, has witnessed a lot of activity over the past eight years, with 261 licensing deals and about 112 co-development deals.
However, when it comes to first-in-class product deals, the market has been relatively slow.
First-in-class, as the US FDA suggests, are drugs that use a novel and unique method of action to treat a medical condition. A first-in-class drug spells
innovation and, though rewarding, can be extremely risky and time-consuming. However, drug companies are willing to take this risk of investment. Around
170 first-in-class products in the pain treatment market are available for co-development and licensing deals. Some of these products have been showcased
in preclinical trials and have proven to provide high rewards for investments.
Studies by GBI Research show that the market for pain treatment is dominated by steroidal anti-inflammatory drugs and opioids and the presence of novel
products has been unable to challenge this dominance. In 2008, the number of patent applications for novel pain therapeutics was 4,970, which dropped to
3,492 in 2012, presenting an average annual decline of 8%. This signifies the unmet therapeutic needs when it comes to new methods of pain treatment.
However, this can be addressed by technological advances and dedicated research efforts.
As mentioned earlier, the active pipeline of pain treatment presently holds about 796 products at various phases of development presenting an increased
diversity of molecular targets. The 122 first-in-class projects in active development stage form 13.6% of the overall pipeline, of which 65 first-in-class
molecular targets reflect an increased level of innovation.
Big Pharma companies such as Novartis, Boehringer Ingelheim, Sanofi, Allergan, and Merck & Co. are reportedly driving the pain treatment and
therapeutics market in the segment of innovation. Merck led the market between 2008 in terms of patent grants, with 59 out of 142 patent applications being
granted. Boehringer Ingelheim was granted 35, Allergan received 34, while Novartis and Sanofi received 30 each.
The pain treatment and management market is largely fragmented and this poses an opportunity for new classes of drugs as numerous blockbuster patents near
Browse the full Global Pain Treatment Market report at http://www.mrrse.com/frontier-pharma-pain